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A B S T R A C T
Depression is twice as common in women as in men, although some concern has been
raised in terms of misdiagnosing depression in men. The incidence of depression in wo-
men varies during the life span. The peak incidence during childbearing years appears
to be associated with cyclic hormonal changes. Women also present with reproductive
-specific mood disorders: pre-menstrual dysphoric disorder (PMDD), depression in preg-
nancy, postpartal mood disorder (PDD) and perimenopausal depressive disorder. Gen-
der differences were repeatedly observed in response to antidepressant medication.
Premenopausal women appear to respond poorly and to show low tolerability to TCAs,
but they tend to show greater responsiveness to the SSRIs. In contrast, men and post-
menopausal women can respond equally to the TCAs and SSRIs. These differences are
contributed to gender differences in pharmacokinetics of antidepressants and to the
influence of menstrual cycle. These findings suggest the need for a gender-specific
approach to the evaluation and management of depression.
Introduction
The interest in gender differences in
depression is relatively new. This is largely
the result of the exclusion of women from
clinical trials in the past and the lack of
data analysis by gender in the studies
that did include women1.
Exclusion of women from clinical tri-
als was due to thalidomide tragedy. How-
ever, the assumption of similarity be-
tween men and women was wrong. The
findings of the past studies suggested dif-
ferences not only in prevalence and clini-
cal presentation of depression but also
the differences in response to various
treatments. In 1993 FDA encouraged the
inclusion of both women and men in clini-
cal trials and the analysis of drug data
separately for men and women (Federal
Registry, July 1993). Thus, information
regarding sex differences in psychophar-
macology will increase in the coming years.
Here we present what is known about
sex differences in epidemiology, hormonal
influences, differences in pharmacokine-
tics of antidepressants and in treatment
response. The aim of our paper was to es-
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tablish gender-specific approach to the
evaluation and treatment of depression.
Gender Differences in
Epidemiology of Depression
Women have a significantly higher
risk for developing depressive disorders
than men. At first, several epidemiologi-
cal studies showed approximately a 2:1
ratio of women to men for major depres-
sive disorder2,3. This ratio has been found
consistently across ethnic groups and in
cross-national studies.
Rates of dystimia are also twice as
common in women4. Moreover, nearly 80%
of individuals with seasonal affective dis-
order are women5. Bipolar affective disor-
der is an exception. Men and women have
an equal lifetime risk for bipolar affective
disorder of approximately 1%2.
The second important issue is that
this difference in prevalence of depres-
sion varies during the life-span. Boys and
girls have the same incidence of depres-
sion6, and in elderly the rate is also simi-
lar between the men and women. The diffe-
rence begins in adolescence6 and persists
until midlife2,7, corresponding roughly to
the childbearing years in women. Major
depression is an essential disorder of
childbearing age. The peak incidence is
between the age 20 and 40.
Although reasons for these differences
are not fully understood, hormonal and
psychosocial influences have direct or in-
direct effect on mood. The new identities
formation in adolescence8, an unhappy
marriage9, the presence of young children
at home10, increased likelihood of experi-
encing victimization or abuse11, and more
frequent help-seeking behavior12 were all
found to make women more vulnerable to
depression compared to men.
Not only women are at greater risk for
depression, but also once depressed, the
symptom presentation in women may dif-
fer from that in men.
In general, the symptoms are similar
in men and women, but women are more
likely to present with atypical symptoms,
such as increased appetite and weight
gain and tend to report more anxiety and
somatic symptoms. Men typically exhibit
classic symptoms of depression, such as
insomnia and weight loss13,14.
However, there is yet unresolved puz-
zle regarding the relationship between
depression and suicide. Depression is the
main precursor of suicide, and depression
is twice as common in women. However,
suicide is three times more common in
men15–18. Men also tend to use more vio-
lent methods of suicide, such as guns and
hanging, which along with less help-seek-
ing behavior may explain their higher
suicide completion rate15. The depression
in males may manifest itself in ways un-
recognized by current diagnostic system.
The male pattern is characterized by irri-
tability, aggressiveness, an acting-out be-
havior, a lowered stress tolerance, and al-
cohol abuse. In general, it is yet to be
determined whether an overrepresenta-
tion of depression in women is simply an
artifact because alcoholism and antiso-
cial behavior mask depression in men18.
In terms of comorbidity, women ap-
pear to have higher rates of comorbid dis-
orders, the most common being anxiety
and eating disorders3,18. In contrast, de-
pressed men have higher rates of comor-
bid alcohol and substance abuse and de-
pendence14.
Course of illness has also been evalu-
ated. Some studies have found a younger
age of onset of depression in women14.
Women also tend to have a longer dura-
tion of episodes19, as well as a greater risk
for chronicity and recurrence20. While men
and women have similar incidence of bi-
polar disorder2, they differ in its course.
Namely, women are more likely to de-
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velop the rapid cycling form of the illness
and may also suffer from more episodes of
depression21.
The Influence of Reproductive
Cycle to Depression in Women
When evaluating a female patient, it
is always important to consider the influ-
ence of the menstrual cycle to her de-
pression22. Periods of increased vulnera-
bility in women are premenstrual period,
pregnancy, postpartal period, and peri-
menopausal years23. All those periods can
trigger a new depressive episode in wo-
men with a history of depression, or gen-
erate a period of vulnerability for devel-
oping a first episode of depression22. Worse-
ning of depression in the premenstrual
phase of the cycle is a rule rather than an
exception. Even 80% of depressed women
reported worsening of their depression
prior to menses. On the other hand, 2–8%
of women does have the criteria for pre-
menstrual dysphoric disorder (PMDD)24.
Pregnancy is usually considered to be
the time of emotional well being. How-
ever, the risk of depression in pregnancy
is estimated to be around 10%25,26. Not
only women are not protected from de-
pression during pregnancy, but also the
infant is not protected from maternal de-
pression. Depression in pregnancy car-
ries the risk of preterm delivery27. Fur-
thermore, infants of depressed mothers
have, in terms of behavioral28,29 and EEG
finding30,31, have brains, as they are de-
pressed themselves. It is unknown whe-
ther those striking findings will extend to
childhood.
The incidence of postpartum depres-
sion between 5% and 10% is the same as
in non-puerperal, age-matched women32.
This period is characterized by rapid
shifts in hormone concentration. Particu-
larly women with bipolar disorder who
discontinue lithium treatment33 or have a
history of postpartal depression34 or ma-
jor depression35 appear to be at highest
risk for postpartum mood disturbance.
There are some groups of women for
whom there is an increased risk for de-
pression in perimenopause2,36. Middle-aged
women presenting with affective liability
should be evaluated for perimenopause
-related depression. Perimenopause-rela-
ted depression is a hormonally mediated,
phase-specific mood disorder, likely to re-
spond to estrogen replacement alone37. It
should be differentiated from the major
depression in perimenopause, that re-
quires treatment with antidepressants.
Women in menopause, on the other hand,
were not found to be in an increased risk
of depression. Characteristics of repro-
ductive-associated mood disorders are
presented in Table 1.
The marked sex differences in rates of
depression that begin with reproductive
age suggest hormonal factors to play a
role in this difference. The onset of pu-
berty, rather than chronological age, is
linked to the increase in rates of depres-
sion in women41. In puberty, female brain
is exposed to estrogen, and hormone lev-
els in women fluctuate cyclically over a
much larger range than in men42. At fe-
male menopause, ovarian secretion shuts
down. In men of the same age, however,
testes continue to produce testosterone,
which is partially converted to estradiol
in the brain42. Men, on the other hand,
seem to be spared from rapid hormone
fluctuations.
Increased incidence of depression in
women in reproductive age is not caused
by specific hormone abnormalities, and
measuring serum FSH and estrogen lev-
els has very limited diagnostic value 20,43.
However, an abnormal response to nor-
mal cyclic hormone fluctuations, at the
synapse level and at the receptor le-
vel38,44,45 is supposed to be involved in the
etiology of depression in vulnerable wo-
men, through the neuromodulatory role
of estrogen on the serotonergic system38,
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which is supposed to play a key role in the
etiology of depression. Animal studies de-
monstrated that ovariectomy causes de-
creases in 5-HT1 binding, 5-HT2A bind-
ing and expression and 5-HT transporter
binding and expression44, the points in
serotonin transmission that are all re-
ported to be altered in depression46. In
humans, women were found to have de-
creased 5-HT2 receptor binding capacity
when compared to men47. The augmenta-
tion of serotonergic activity in postmeno-
pausal women with estrogen replacement
therapy48 supports the evidence of the re-
lation between estrogen and serotonergic
system in humans. Gender-related differ-
ences were also found in the rate of sero-
tonin synthesis, which has been found to
be as much as 52% greater in males than
in females49. The reason for this remark-
able difference is not clear. All subjects
were in age from 18 to 35 years, without
personal or family psychiatric history.
The authors presumed early serotoniner-
gic events in serotonin synthesis in the
brain organization, or effects of circulat-
ing gonadal hormones. This is one of the
largest differences observed to date be-
tween the brains of the healthy men and
women, which is not related to hormone-
-binding sites49. Regarding peripheral se-
rotonergic markers, healthy women were
consistently found to have lower platelet
serotonin levels than healthy men50–52.
Depressed drug-free women were also
found to have decreased platelet seroto-
nin concentration when compared to de-
pressed men50. These data suggest that
women in their childbearing years, either
healthy or depressed, may have decreased
serotonergic function, associated with
physiological fluctuations in gonadal hor-
mone concentrations. Tryptophan, a sero-
tonin precursor, is converted to serotonin
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TABLE 1
REPRODUCTIVE-ASSOCIATED MOOD DISORDERS38–40
Disorder Endocrine environment Special issues
PMDD •Cyclic changes in gonadal
hormone concentrations
•Also occurs in anovulatory
cycles and in the absence of
lutheal phase
•Serotonergic antidepressants
work better than noradrenergic




•Very gradual rise in estrogen
levels
•Risk of preterm delivery










•Thyroid status should be
checked, while thyroid
disfunction is an associated
factor
•In women with a previous
episode of PDD antidepres-




•Variable decline in estrogen
concentrations, estrogen
unopposed by progesterone
due to anovulatoy cycles
•Estrogen replacement therapy
is the first line of treatment
in the brain, or, alternatively, to kynu-
renine in liver. Estrogen enhances the
kynurenine pathway in the liver. There-
fore, the availability of tryptophan may
be lower, and may eventually decrease se-
rotonin content in the brain 53. Given that
stress plays a major role in the onset of
depression, gender differences in the re-
sponse to stress could increase women’s
vulnerability to depression54. Interesting
finding is that decreased cortisol suppres-
sion to dexamethasone was found during
luteal phase when compared to the folli-
cular phase in the same healthy women55.
This change is believed to be related to ei-
ther increased estradiol or progesterone,
or their interaction, during the luteal
phase. The worsening of depression in
premenstrual phase could be attributed
to increased resistance to glucocorticoids
induced by these hormonal changes. Sim-
ilarly, oral contraceptives, particularly
with a high progestin content, may in-
duce depression53.
In contrast to changing hormonal mi-
lieu during reproductive age, postmeno-
pausal women have low estrogen and pro-
gesterone levels. The decline in rate of
depression in this age group2 suggests
that estrogen deficiency is not a risk fac-
tor for depression. This finding reinforces
the hypothesis that it is the change in es-
trogen that may be the critical hormonal





The differences in pharmacokinetics
have been demonstrated in all of the ar-
eas of absorption, distribution, metabo-
lism and elimination56. However, data
are limited until recently, due to previ-
ously mentioned exclusions of women
from clinical trials. This is unfortunate,
because women are significantly more
likely than men to be prescribed antide-
pressants. When compared to men,
women were found to have slower gastric
emptying time, lower gastric acid secre-
tion, lower body weight, lower blood vol-
ume, higher percentage of body fat, lower
plasma protein binding, higher cerebral
blood flow, lower hepatic biotransforma-
tion and lower renal clearance57.
The possible application of these find-
ings is that women tend to have higher
plasma levels of antidepressants and high-
er incidence of adverse events thereafter.
However, the menstrual cycle may affect
pharmacokinetics in a different manner.
Specifically, the late luteal or premen-
strual phase has been associated with
possible sodium retention and increased
total body water, possible increase in he-
patic metabolism and possible increase in
creatinin clearance57. The consequence of
these changes is the decrease in antide-
pressant blood concentrations. These find-
ings seem not to be applied to fluoxetine,
due to its long half-life1.
Gender Differences in Treatment
Response
Gender differences were also observed
in terms of treatment response to antide-
pressant drugs. Imipramine was the first
antidepressant widely used and has long
been the gold standard against which
newer agents have been compared. It
may not be equally effective in men and
women, however. That women may be
less responsive than men to imipramine
was notified as long as several decades
ago. The first study to demonstrate this
difference was the Raskin study58, when
women and men were stratified by gen-
der and age (younger than 40 years, and
40 years or older). In men, imipramine re-
sponse rates for both groups did not differ
and were significantly better than pla-
cebo. Response rate in women, however,
differed by age group. While women in
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the age of 40 years or older showed a re-
sponsiveness to imipramine similar to
that of men, younger women were no
more responsive to imipramine than to
placebo58. These findings are consistent
with the study carried out 25 years later.
In meta-analysis of 35 studies by Ha-
milton, response rates to imipramine we-
re reported separately by gender59. Over-
all response rates to imipramine differed
by 11% between men and women. Women
showed lower response to imipramine
than men, despite higher plasma concen-
trations.
The old age interest group60 in Britain
has found that women taking dothiepine
were more likely to experience a recurrence
of depression, than men were. Further-
more, women taking placebo were also sig-
nificantly more likely to suffer recurrence
of depression compared with men taking
placebo. These findings suggest that wo-
men have a worse prognosis in terms of a
risk of recurrence of depression.
Really interesting and important find-
ings were found in comparison between
imipramine and sertraline61. Men res-
ponded significantly better to imipra-
mine. Women in general responded to
sertraline better than to imipramine.
However, when data were analyzed sepa-
rately due to menopausal status, it was
found that premenopausal women re-
sponded better to sertraline, whereas re-
sponse rates of postmenopausal women
were similar in both drugs!
The authors suggested that female
ovarian hormones may enhance response
to SSRIs, or inhibit the response to TCAs.
The reason for this difference may be also
related to sex differences in depressive
subtypes, i.e. more atypical depression in
women1. The difference disappears in
menopause. In this study gender differ-
ence in drug-tolerability was also noted.
Women taking imipramine were more
likely to drop out from the study than
that taking sertraline. Premenopausal
women were more than 3 times as likely
to drop out of imipramine treatment than
postmenopausal women61.
When comparing imipramine and pa-
roxetine in outpatients62, women respon-
ded significantly better to paroxetine than
to imipramine, but women responded bet-
ter to both active treatments compared
with placebo. It is noteworthy that in
men, however, because of high placebo re-
sponse rates, there were no significant
differences among the three treatment
regimens. Women had lower placebo re-
sponse than men in this study.
In contrast to previous two studies
that demonstrated better response to
SSRIs paroxetine and sertraline than to
imipramine in women, this difference
was not found for fluoxetine62. Women re-
sponded equally to both fluoxetine and
imipramine. Unfortunately, there were no
comparison data given for placebo or for
men. In this study fluoxetine was better
tolerated than imipramine63. A recent
study, however, demonstrated that de-
pressed women younger than 44 years re-
sponded significantly better to fluoxetine
than to noradrenergic agent, maprotili-
ne64. The men had similar response across
different age groups. While women are
reported to tolerate better imipramine
than sertraline61, the whole SSRI group
seems to be tolerated similar in males
and females65.
There was also a meta-analysis of 8
placebo-controlled studies of citalopram
in women and men with depression66.
Women treated with either citalopram or
placebo showed a significantly greater re-
sponse to treatment than men, although
drug-placebo difference was the same in
both men and women66. Why do premeno-
pausal women respond better to SSRIs
than to other classes of antidepressants?
We hypothesize that SSRI treatment could
reverse lower serotonergic function50–53,
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associated with cyclic changes in gonadal
hormone levels.
Gender differences were also observed
in augmentation studies. As long as sev-
eral decades ago, a trend for greater effi-
cacy in women using T3 augmentation of
antidepressant treatment67,68 was noted.
More specifically, addition of T3 to imi-
pramine regimen was found to accelerate
the recovery of the women but not the
men, beginning as early as the third day
of treatment68. However, clinical impro-
vement may be attributed rather to the
correction of mild thyroid dysfunction69,
since women have ten times the incidence
of thyroid disease as men53. On the other
hand, a trend for greater efficacy of either
T3 or T4 antidepressant augmentation
was reported, in women with no differ-
ence in baseline serum T3, free T4 and
TSH levels in responders and non-res-
ponders70.
While the efficacy of lithium augmen-
tation of antidepressant response has
been documented since the early 1980s,
the data were reported by gender in only
2 studies71,72, when lithium was added to
different classes of antidepressants. In
both studies, significantly better response
rate was achieved in women. However,
the recent literature analysis indicated
similar response rates for lithium in bipo-
lar and related affective disorders73.
Estrogen was suggested to play a per-
missive role in imipramine-induced chan-
ges in serotonergic receptor binding, with
possible clinical significance for patients
with ovarian hormone deficiency. Prelim-
inary studies suggest that estrogen re-
placement therapy (ERT) given in con-
ventional doses (high-0.05 and low-0.025
mg) to antidepressant treatment may en-
hance mood in postmenopausal women48,74.
However, the lack of double-blind studies
limits any conclusion from currently ava-
ilable data.
No specific relationship between lower
testosterone levels and depression in men
has been established75. Recent data, how-
ever, suggest the possibility that testos-
terone deficiency leads to late life mild
depression76. Unlike in women, it is not
clear whether aging men experience »an-
dropause«, whether there is the testoster-
one »threshold« associated with CNS ef-
fects and/or whether are some men
particularly vulnerable to testosterone-
-mediated depression76. Anecdotal re-
ports and uncontrolled data suggest that
in some men with hypogonadism comor-
bid major depression remits with testos-
terone replacement76.
In terms of electroconvulsive treat-
ment (ECT), the data suggest that wo-
men have a lower seizure threshold77, a
more favorable response rate and less se-
vere side effects men78. However, data re-
garding efficacy by gender are inconsis-
tent1. The inability to provide treatment
in double-blind fashion is a consistent
confounding factor in interpreting the im-
portance of those findings1.
Conclusion
Although research on gender effects in
depression has been limited, existing lit-
erature shows clear evidence of sex-re-
lated differences 79. In general, younger
premenopausal women appear to respond
poorly and show low tolerability to TCAs,
but tend to show greater responsiveness
to the SSRIs. In contrast, men and post-
menopausal women can respond equally
well or better to the TCAs.
Because of pharmacokinetic differen-
ces and increased sensitivity to side ef-
fects, women may require a lower dosage
of some medications.
Because of a possible risk of recur-
rence of depression among women, a long
-term treatment may be required. Meno-
pausal status may be an important con-
sideration not only in choosing an antide-
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pressant agent, but also in deterring aug-
mentation strategies. Similarly, the men-
strual cycle may affect pharmacokinetics
of antidepressant agents of women. In-
creasing the dosage of SSRIs premen-
strual can result in a very rapid response.
The preliminary nature of these con-
clusions suggests need for future research.
Clearly, more data are needed to under-
stand the feature.
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RAZLI^ITOST DEPRESIJE U @ENA I MU[KARACA
S A @ E T A K
Depresija se javlja dvostruko ~e{}e u `ena, premda postoji podatak da se ona ~esto
kod mu{karaca previdi i rje|e dijagnosticira. Incidencija depresije u `ena razlikuje se
obzirom na dob. S najve}om u~estalo{}u javlja se tijekom fertilne dobi, {to se tuma~i
cikli~kim djelovanjem hormona. Razlikujemo ~etiri poreme}aja specifi~na za repro-
duktivno razdoblje: premenstrualni disfori~ni poreme}aj, depresija u trudno}i, post-
partalna depresija, te depresivni poreme}aj u perimenopauzi. Razlike obzirom na spol
opa`ene su tako|er u odgovoru na antidepresivnu terapiju. Dok je u `ena u fertilnoj
dobi imipramin slabije u~inkovit i podno{ljiv, za razliku od selektivnih inhibitora po-
novne pohrane serotonina (SSRI), u `ena u menopauzi i mu{karaca ta se razlika ne
nalazi. Razlika se nastoji protuma~iti razlikama u farmakokinetici antidepresiva te
utjecaju hormona. Sukladno spomenutim navodima, smatramo da je prilikom dijagno-
sticiranja i lije~enja depresije va`no uzeti u obzir i spol bolesnika.
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